Screening of prediabetes and Type 2 Diabetes in Pediatrics

- Annexes

Annex Table 1.

Declaration of Conflict of Interests

The members of the guideline development/ adaptation group and the external review group have no academic, financial, or competing interests to declare and none of them were involved in the development of the original source guideline(s).

Any identified potential COI has been reported below.

Egyptian Pediatric Clinical Practice Guidelines Committee (EPG)

Guideline Development/ Adaptation Group (Clinicians subgroup)

Name

Affiliation, Area of expertise / Country / Primary location [work]

Contribution

Professor Amany Kamal El Hawary

Professor of pediatrics, Director of Pediatric Endocrinology and Diabetes unit, Mansoura University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Amina M. Abdel Wahab

Professor of pediatrics, Pediatric Endocrinology and Diabetes, Suez Canal University.

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Ashraf A. Elsharkawy

Professor of pediatrics, Pediatric Endocrinology and Diabetes unit, Mansoura University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Basma Abdel Moez

Professor of Pediatrics, Head of Pediatric Endocrinology, El Menya University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Hanaa Abdel Latif

Professor of pediatrics, Head of Pediatric Endocrinology and Diabetes unit, Assiut University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Lubna Fawaz

Professor of pediatrics, Former director of the pediatric diabetes, endocrine and metabolism unit, Cairo University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Mona Mamdouh Hassan

Professor of pediatrics, Head of the Diabetes, Endocrine and Metabolism Pediatric Unit, Cairo University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Nora El Sayed Badawi

Professor of Pediatrics, Diabetes, Endocrine and Metabolism Pediatric Unit, Cairo University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Randa M Matter

Professor of pediatrics, Pediatric and Adolescence Diabetes Unit, Ain-Shams University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Safinaz El Habashy

Professor of pediatrics, Former Head of the Pediatric and Adolescence Diabetes Unit, Ain-Shams University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Professor Wiam Al Farouk Younis

Professor of pediatrics, Pediatric Diabetes and Endocrine unit, AFCM

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Assistant Professor Shaymaa Elsayed Abdel Meguid

Assistant professor of Pediatrics, Pediatric Endocrinology and Diabetology Unit, Faculty of Medicine, Alexandria University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Dr. Hanan Hassan Aly

Assistant professor of pediatrics, Pediatric and Adolescence Diabetes Unit, Ain-Shams University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Dr. Mona Karem Amin

Assistant professor of pediatrics, Pediatric Diabetes and Endocrine unit, Suez canal University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Dr. Nouran Y Salah El-Din

Assistant professor of pediatrics, Pediatric and adolescence diabetes unit, Ain-shams University, AFCM

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Dr. Ramy Saleh Morsy

Lecturer of pediatrics, Pediatric diabetes and endocrine unit, AFCM

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Dr. Remon Magdy

Assistant professor of pediatrics, Pediatric diabetes and endocrinology unit, Fayoum University

Author contributed in formulating the following recommendations, PIPOH, implementation tools, health question, reviewing the literature, discussion and adaptation

Egyptian Pediatric Clinical Practice Guidelines Committee (EPG)

Guideline Development/ Adaptation Group (Guideline Methodologists subgroup)

Name

Affiliation, Area of expertise / Country / Primary location [work]

Contribution

Prof. Ashraf Abdel Baky

Professor of Pediatrics

Ain Shams University, Egypt

Founder and Chair of EPG

Overseeing the adolopment process of the guidelines, training and education of new members, revision of the final draft, and organizing online meetings of GDG

Dr. Yasser Sami Amer

1. Pediatrics Department and Clinical Practice Guidelines and Quality Research Unit, Quality Management Department, King Saud University Medical City, Riyadh, Saudi Arabia;

2. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia;

3. Chair, Adaptation Working Group, Guidelines International Network (GIN), Perth, Scotland

4. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil.

Overseeing the adolopment process of the guidelines, training and education of new members, participating in writing up the methodology of adaptation process, guideline appraisal, and revision of the final draft

Dr. Nahla Gamaleldin

Lecturer of pediatrics, Faculty of Medicine, Modern University for Technology and Information (MTI), Egypt

Participating in multiple steps of the guideline adaptation process, Writing the methodology of adaptation process and revised the whole document.

External Reviewers Group (ERG)

External Reviewer(s) for Clinical Content

Name

Affiliation, Area of expertise / Country / Primary location [work]

Ghada Mohammad Anwar

Prof. of pediatric diabetes and endocrinology/ Cairo University

International Peer Reviewers

External Reviewer(s) for methodology

Prof. Iván D. Flórez

Department of Pediatrics, University of Antioquia, Medellín, Colombia,

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada,

Leader, AGREE Collaboration (Appraisal of Guidelines for Research & Evaluation)

Director, Cochrane Colombia

Prof. Airton Tetelbom Stein

Professor Titular de Saúde Coletiva, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil

Professor Adjunto, Universidade Luterana do Brasil (Ulbra), Canoas, Brazil

Coordenador de Diretrizes Clínicas, Grupo Hospitalar Conceição, Porto Alegre, Brazil

4. Member, Board of Trustees, Guidelines International Network (G-I-N)

➡️Web annexes

The following annexes can be added as a package of standalone supplementary documents.

Keywords: The MeSH terms for "Guideline for the prevention of. " on PubMed are: screening, T2 D, prediabetes, children, adolescents. OGTT

Annex Table 2. Results of the AGREE II assessment of the three source guidelines for ISPAD 2022

AGREE II/ CPGs	ISPAD 2022
Domain 1 (Scope)	% 89
Domain 2 (Stakeholder)	% 75
Domain 3 (Rigour)	% 59
Domain 4 (Clarity)	% 97
Domain 5 (Applicability)	% 94
Domain 6 (Independence)	% 73
Overall assessment .	%
Recommend for use (Overall assessment .)	YES

➡️Annex Table 3. Annex Nurses and Parents Educational Guide in Arabic

Appendix Table 4. The RIGHT-Ad@pt checklist
7 sections, 27 topics, and 34 items		Assessment	Page(s)*	Note(s)
BASIC INFORMATION
Title/subtitle
1	Identify the report as an adaptation of practice guideline(s), that is include "guideline adaptation", "adapting", "adapted guideline/recommendation(s)", or similar terminology in the title/subtitle.	☒ Yes ☐ No ☐ Unclear
2	Describe the topic/focus/scope of the adapted guideline.	☒ Yes ☐ No ☐ Unclear
Cover/first page
3	Report the respective dates of publication and the literature search of the adapted guideline.	☒ Yes ☐ No ☐ Unclear
4	Describe the developer and country/region of the adapted guideline.	☒ Yes ☐ No ☐ Unclear
Executive summary/abstract
5	Provide a summary of the recommendations contained in the adapted guideline.	☒ Yes ☐ No ☐ Unclear
Abbreviations and acronyms
6	Define key terms and provide a list of abbreviations and acronyms (if applicable).	☒ Yes ☐ No ☐ Unclear
Contact information of the guideline adaptation group
7	Report the contact information of the developer of the adapted guideline.	☒ Yes ☐ No ☐ Unclear
SCOPE
Source guideline(s)
8	Report the name and year of publication of the source guideline(s), provide the citation(s), and whether source authors were contacted.	☒ Yes ☐ No ☐ Unclear
Brief description of the health problem(s)
9	Provide the basic epidemiological information about the problem (including the associated burden), health systems relevant issues, and note any relevant differences compared to the source guideline(s).	☒ Yes ☐ No ☐ Unclear
Aim(s) and specific objectives
10	Describe the aim(s) of the adapted guideline and specific objectives, and note any relevant differences compared to the source guideline(s).	☒ Yes ☐ No ☐ Unclear
Target population(s)
11	Describe the target population(s) and subgroup(s) (if applicable) to which the recommendation(s) is addressed in the adapted guideline, and note any relevant differences compared to the source guideline(s).	☒ Yes ☐ No ☐ Unclear
End-users and settings
12	Describe the intended target users of the adapted guideline, and note any relevant differences compared to the source guideline(s).	☒ Yes ☐ No ☐ Unclear
13	Describe the setting(s) for which the adapted guideline is intended, and note any relevant differences compared to the source guideline(s).	☒ Yes ☐ No ☐ Unclear
RIGOR OF DEVELOPMENT
Guideline adaptation group
14	List all contributors to the guideline adaptation process and describe their selection process and responsibilities.	☒ Yes ☐ No ☐ Unclear
Adaptation framework/methodology
15	Report which framework or methodology was used in the guideline adaptation process.	☒ Yes ☐ No ☐ Unclear
Source guideline(s)
16	Describe how the specific source guideline(s) was(were) selected.	☒ Yes ☐ No ☐ Unclear
Key questions
17	State the key questions of the adapted guideline using a structured format, such as PICO (population, intervention, comparator, and outcome), or another format as appropriate.	☒ Yes ☐ No ☐ Unclear
18	Describe how the key questions were developed/modified, and/or prioritized.	☐ Yes ☒ No ☐ Unclear
Source recommendation(s)
19	Describe how the recommendation(s) from the source guideline(s) was(were) assessed with respect to the evidence considered for the different criteria, the judgements and considerations made by the original panel.	☐ Yes ☒ No ☐ Unclear
Evidence synthesis
20	Indicate whether the adapted recommendation(s) is/are based on existing evidence from the source guideline(s), and/or additional evidence.	☐ Yes ☒ No ☐ Unclear
21	If new research evidence was used, describe how it was identified and assessed.	☐ Yes ☒ No ☐ Unclear	NA
Assessment of the certainty of the body of evidence and strength of recommendation
22	Describe the approach used to assess the certainty/quality of the body/ies of evidence and the strength of recommendations in the adapted guideline and note any differences (if applicable) compared to the source guideline(s).	☐ Yes ☒ No ☐ Unclear	NA
Decision-making processes
23	Describe the processes used by the guideline adaptation group to make decisions, particularly the formulation of recommendations.	☒ Yes ☐ No ☐ Unclear
RECOMMENDATIONS
Recommendations
24	Report recommendations and indicate whether they were adapted, adopted, or de novo.	☒ Yes ☐ No ☐ Unclear
25	Indicate the direction and strength of the recommendations and the certainty/quality of the supporting evidence and note any differences compared to the source recommendations(s) (if applicable).	☒ Yes ☐ No ☐ Unclear
26	Present separate recommendations for important subgroups if the evidence suggests important differences in factors influencing recommendations and note any differences compared to the source recommendations(s) (If applicable).	☒ Yes ☐ No ☐ Unclear
Rationale/explanation for recommendations
27	Describe the criteria/factors that were considered to formulate the recommendations or note any relevant differences compared to the source guideline(s) (if applicable).	☒ Yes ☐ No ☐ Unclear
EXTERNAL REVIEW AND QUALITY ASSURANCE
External review
28	Indicate whether the adapted guideline underwent an independent external review. If yes, describe the process.	☒ Yes ☐ No ☐ Unclear
Organizational approval
29	Indicate whether the adapted guideline obtained organizational approval. If yes, describe the process.	☒ Yes ☐ No ☐ Unclear	SNS & NEBMC
FUNDING, DECLARATION, AND MANAGEMENT OF INTEREST
Funding source(s) and funder role(s)
30	Report all sources of funding for the adapted guideline and source guideline(s), and the role of the funders.	☒ Yes ☐ No ☐ Unclear
Declaration and management of interests
31	Report all conflicts of interest of the adapted and the source guideline(s) panels, and how they were evaluated and managed.	☒ Yes ☐ No ☐ Unclear
OTHER INFORMATION
Implementation
32	Describe the potential barriers and strategies for implementing the recommendations (if applicable).	☒ Yes ☐ No ☐ Unclear
Update
33	Briefly describe the strategy for updating the adapted guideline (if applicable).	☒ Yes ☐ No ☐ Unclear
Limitations and suggestions for further research
34	Describe the challenges of the adaptation process, the limitations of the evidence, and provide suggestions for future research.	☐ Yes ☒ No ☐ Unclear	--